Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Sulfated polysaccharides, particularly those derived from marine algae (such as fucoidan, carrageenan, and ulvan), have been investigated for their antiviral effects, including potential benefits against hepatitis viruses. Several in vitro and limited in vivo studies demonstrate that these compounds can inhibit the replication of hepatitis B virus (HBV) and hepatitis C virus (HCV). The proposed mechanisms include interference with viral attachment and entry, modulation of immune responses, and inhibition of viral polymerases. For example, fucoidan has been shown in laboratory experiments to suppress HBV antigen secretion and DNA replication in hepatoma cell lines. Animal studies provide some support, showing reduced viral loads and alleviated liver inflammation in hepatitis models treated with sulfated polysaccharides.

However, despite promising preclinical data, there is a lack of robust human clinical trials evaluating the efficacy and safety of sulfated polysaccharides in treating hepatitis. Most evidence remains preliminary, with limited translation to clinical practice. Thus, while there is a scientific rationale and some experimental support for their use, the overall quality and quantity of evidence remain low, justifying a rating of 2 out of 5. Further well-designed clinical studies are needed to establish their therapeutic value for hepatitis in humans.

More about Sulfated polysaccharide
More about Hepatitis

Other ingredients used for Hepatitis

Other health conditions supported by Sulfated polysaccharide

Products containing Sulfated polysaccharide